Infinity Stone Refines Graphite to 99.73% Purity, Plans Spin Out of Rockstone Graphite Project
Highlights Infinity Stone successfully refines graphite samples from its Rockstone Graphite Project to 99.73% Cg…
Year: 2023
DelphX Announces Closing of $660,200 Non-Brokered Unit Financing
Toronto, Ontario–(Newsfile Corp. – March 3, 2023) – DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB:…
Doubleview Provides Update on HAT Project 2021 and 2022 Drill Data
Vancouver, BC, Mar 3, 2023 – (ACN Newswire) – Doubleview Gold Corp. (TSXV: DBG) (OTCQB:…
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing…
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) — Ractigen Therapeutics announced today that the U.S….
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”),…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule…
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase…
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE, Wash. and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no…
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
— Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line…
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),…
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in…
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
IRVINE, Calif., March 03, 2023 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global…
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”),…
Societal CDMO to Participate at 35th Annual Roth Conference
SAN DIEGO and GAINESVILLE, Ga., March 03, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal…
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…
Oculis Announces US Public Listing on NASDAQ
Oculis Announces US Public Listing on NASDAQ Closing of business combination with European Biotech Acquisition…
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (“Eagle” or the…